GlassScriptPhysician profile
Michael Low Cardenas
NPI 1043639081
$1,551.93
in general payments reported to CMS, 2019-2025
27 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.97 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $171.29 | 2025 | Brukinsa, Tevimbra |
| Merck Sharp & Dohme LLC | $166.95 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $139.86 | 2025 | |
| Genentech USA, INC. | $131.29 | 2025 | Polivy, Tecentriq |
| Novocure INC. | $114.96 | 2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Legend Biotech USA INC. | $102.85 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $77.84 | 2025 | Xpovio |
| Caris Mpi, INC. | $60.54 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $60.18 | 2025 | Erleada, Rybrevant, Carvykti |
| Agios Pharmaceuticals, INC. | $59.25 | 2025 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $56.00 | 2025 | Danziten |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.16 | 2025 | |
| Geron Corporation | $39.42 | 2025 | Rytelo |
| Daiichi Sankyo INC. | $33.94 | 2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $33.16 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $28.71 | 2025 | |
| Iovance Biotherapeutics, INC. | $28.16 | 2025 | Amtagvi |
| Astellas Pharma US INC | $26.99 | 2025 | Xtandi |
| Pharmaessentia USA Corporation | $26.64 | 2025 | Besremi |
| Tersera Therapeutics LLC | $21.92 | 2025 | Zoladex |
| Lilly USA, LLC | $21.53 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.84 | 2025 | Ultomiris |
| Sobi, INC | $18.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.13 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.14 | 2025 | Libtayo |
| Kyowa Kirin, INC. | $15.65 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cardenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.